HONG KONG – Shanghai No. 1 Intermediate People's Court sentenced two foreign private investigators linked to the Glaxosmithkline plc (GSK) China bribery scandal to prison on Monday. Read More
SHANGHAI – Sotio AS, of Prague, has expanded its China footprint with the opening of a GMP, clean-room lab for the production of active cellular immunotherapy treatments against cancer diseases. Read More
SHANGHAI – Cellular Biomedicine Group Inc., a stem cell and immunotherapy company headquartered in Shanghai, has acquired Beijing Agreen Biotech Co. Ltd. The deal will bring patents, people and the promise of revenue to its new owner. Read More
HONG KONG – Researchers here have shown for the first time that during bone formation and growth, cartilage cells or chondrocytes survive and develop into mature osteoblasts, the cells that form new bone, contradicting the long-held tenet that chondrocytes and osteoblasts are separate independently developing cell types. Read More
SHANGHAI – Yabao Pharmaceutical Co. Inc. has agreed to co-develop with Le Sun Pharmaceutical Ltd. its leading PLK/PI3K dual inhibitor LS-008. Read More
HONG KONG – Shenyang, China-based 3SBio Inc. has entered an exclusive licensing agreement with Korean biotech Dinona Inc. for 3SBio to develop, manufacture and market leukotuximab in Greater China to offer better treatment to Chinese leukemia patients and reinforce its blood-related disorders pipeline. Read More
Celltrion Inc., of Incheon, South Korea, reported Monday that it has filed a biologic license application for its Remsima, a biosimilar of Janssen Biotech Inc.'s Remicade (infliximab). Read More
